Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose S-Ketamine for Postpartum Depression Prevention
NCT03927378Completed
- Sponsor
- Peking University First Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in postpartum depression (PPD) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Incidence of depression at 42 days after childbirth. Started Jun 2020; status: completed.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT03927378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927378.